Omeros Corporation (OMER) Income Statement Analysis

See more : Intertape Polymer Group Inc. (ITPOF) Income Statement Analysis – Financial Results

Complete financial analysis of Omeros Corporation (OMER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Omeros Corporation, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Omeros Corporation (OMER)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.omeros.com

About Omeros Corporation

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Revenue	0.00	0.00	0.00	73.81M	111.81M	29.87M	64.83M	41.62M	13.51M	539.00K	1.60M	6.02M	4.52M	2.11M	1.44M	1.17M	1.92M	200.00K	0.00
Cost of Revenue	69.78M	952.00K	1.39M	902.00K	865.00K	512.00K	1.08M	1.41M	1.04M	26.73M	18.33M	18.46K	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-69.78M	-952.00K	-1.39M	72.91M	110.94M	29.36M	63.75M	40.21M	12.47M	-26.19M	-16.73M	6.00M	4.52M	2.11M	1.44M	1.17M	1.92M	200.00K	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	98.78%	99.23%	98.29%	98.34%	96.61%	92.29%	-4,858.81%	-1,045.38%	99.69%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
Research & Development	114.87M	112.72M	118.78M	110.82M	109.70M	89.86M	55.60M	50.70M	48.38M	47.95M	36.30M	31.92M	23.72M	23.47M	16.93M	17.85M	15.92M	20.53M	5.80M
General & Administrative	0.00	50.67M	54.84M	72.70M	64.63M	51.72M	52.04M	43.78M	35.33M	22.60M	15.82M	10.99M	8.22M	8.75M	0.00	7.85M	10.40M	3.63M	0.00
Selling & Marketing	0.00	3.20K	7.80K	5.60K	8.00K	2.50M	300.00K	672.00K	885.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	49.66M	50.67M	54.84M	72.70M	64.63M	51.72M	52.04M	43.78M	35.33M	22.60M	15.82M	10.99M	8.22M	8.75M	5.27M	7.85M	10.40M	3.63M	1.90M
Other Expenses	-69.78M	0.00	1.74M	654.00K	1.55M	1.78M	1.44M	945.00K	1.03M	-207.00K	574.00K	130.00K	0.00	0.00	0.00	372.00K	-125.00K	179.00K	0.00
Operating Expenses	94.75M	163.39M	173.62M	183.51M	174.32M	141.58M	107.64M	94.48M	83.71M	70.55M	52.12M	42.91M	31.93M	32.21M	22.20M	25.70M	26.32M	24.15M	7.71M
Cost & Expenses	164.53M	163.39M	173.62M	184.41M	175.19M	142.09M	108.72M	95.89M	84.75M	70.55M	52.12M	42.91M	31.93M	32.21M	22.20M	25.70M	26.32M	24.15M	7.71M
Interest Income	0.00	4.06M	17.93K	654.00K	22.66K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	333.00K
Interest Expense	14.50M	22.70M	19.67M	26.75M	22.66M	16.25M	11.03M	7.82M	3.57M	3.47M	2.37M	1.73M	1.88M	1.54M	2.20M	335.00K	151.00K	91.00K	0.00
Depreciation & Amortization	920.00K	952.00K	1.39M	1.62M	1.79M	962.00K	551.00K	300.00K	209.00K	326.00K	302.00K	320.00K	435.00K	472.00K	451.00K	434.00K	375.00K	232.00K	341.00K
EBITDA	-163.61M	-162.44M	-172.23M	-168.02M	-144.25M	-122.47M	-41.90M	-58.63M	-71.31M	-69.88M	-37.13M	-36.40M	-26.23M	-27.24M	-18.44M	-24.09M	-22.57M	-22.45M	-7.37M
EBITDA Ratio	0.00%	0.00%	0.00%	-148.95%	-55.30%	-369.76%	-65.48%	-128.15%	-519.71%	-13,026.90%	-3,102.50%	-610.35%	-612.80%	-1,521.33%	-1,535.87%	-2,027.26%	-1,255.69%	-11,771.00%	0.00%
Operating Income	-164.53M	-163.39M	-173.62M	-110.60M	-63.38M	-112.22M	-43.90M	-54.28M	-71.24M	-70.01M	-50.52M	-36.89M	-27.41M	-30.11M	-20.76M	-24.53M	-24.40M	-23.95M	-7.71M
Operating Income Ratio	0.00%	0.00%	0.00%	-149.84%	-56.69%	-375.73%	-67.71%	-130.42%	-527.34%	-12,988.50%	-3,157.25%	-612.50%	-605.88%	-1,430.21%	-1,437.53%	-2,096.15%	-1,268.69%	-11,976.50%	0.00%
Total Other Income/Expenses	-10.39M	-18.64M	-17.93M	-39.47M	-21.10M	-27.46M	-9.59M	-12.47M	-3.86M	-3.67M	10.72M	-1.56M	-1.14M	855.00K	-331.00K	698.00K	1.31M	1.18M	341.00K
Income Before Tax	-174.92M	-182.03M	-191.55M	-150.07M	-84.49M	-139.69M	-53.48M	-66.75M	-75.10M	-73.67M	-39.80M	-38.44M	-26.66M	-27.72M	-18.89M	-23.83M	-23.09M	-22.78M	-7.37M
Income Before Tax Ratio	0.00%	0.00%	0.00%	-203.31%	-75.57%	-467.68%	-82.50%	-160.38%	-555.90%	-13,668.46%	-2,487.25%	-638.39%	-589.35%	-1,316.67%	-1,307.96%	-2,036.50%	-1,200.78%	-11,388.50%	0.00%
Income Tax Expense	0.00	-210.81M	-365.76M	-12.01M	22.42M	-12.93M	11.92M	8.46M	4.39M	2.94M	2.94M	1.54M	1.14M	-855.00K	331.00K	707.00K	26.00K	270.00K	0.00
Net Income	-117.81M	28.78M	194.24M	-138.06M	-106.91M	-126.76M	-53.48M	-66.75M	-75.10M	-73.67M	-39.80M	-38.44M	-28.55M	-29.25M	-21.09M	-23.83M	-23.09M	-22.78M	-7.37M
Net Income Ratio	0.00%	0.00%	0.00%	-187.04%	-95.62%	-424.39%	-82.50%	-160.38%	-555.90%	-13,668.46%	-2,487.25%	-638.39%	-630.99%	-1,389.60%	-1,460.46%	-2,036.50%	-1,200.78%	-11,388.50%	0.00%
EPS	-1.88	0.46	3.12	-2.41	-2.16	-2.61	-1.17	-1.65	-2.00	-2.22	-1.39	-1.59	-1.29	-1.37	-2.92	-8.26	-1.62	-1.60	-0.52
EPS Diluted	-1.88	0.46	3.12	-2.41	-2.16	-2.61	-1.17	-1.65	-2.00	-2.22	-1.39	-1.59	-1.29	-1.37	-2.92	-8.26	-1.62	-1.60	-0.52
Weighted Avg Shares Out	62.74M	62.74M	62.34M	57.18M	49.52M	48.58M	45.54M	40.45M	37.56M	33.23M	28.56M	24.16M	22.21M	21.42M	7.22M	2.88M	14.27M	14.27M	14.27M
Weighted Avg Shares Out (Dil)	62.74M	62.74M	62.34M	57.18M	49.52M	48.58M	45.54M	40.45M	37.56M	33.23M	28.56M	24.16M	22.21M	21.42M	7.22M	2.88M	14.27M	14.27M	14.27M

Omeros Corporation (OMER) CEO Greg Demopulos on Q3 2021 Results - Earnings Call Transcript

November 9, 2021seekingalpha.com

Omeros Corporation (OMER) CEO Greg Demopulos on Q3 2021 Results - Earnings Call Transcript

Omeros: Q3 Earnings Insights

November 9, 2021benzinga.com

Omeros (NASDAQ:OMER) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Omeros Corporation Reports Third Quarter 2021 Financial Results

November 9, 2021businesswire.com

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders,...

Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years

November 5, 2021benzinga.com

Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy. Treatment with narsoplimab showed a median reduction in proteinuria of 64.4%.

Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial

November 5, 2021businesswire.com

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy. Treatment with narsoplimab in this trial was associated with an unprecedented median reduction...

Omeros' Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis

November 5, 2021businesswire.com

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first report describing the effects of lectin-pathway inhibition by narsoplimab on urinary complement levels in kidney disease was presented yesterday at the Annual Meeting of the American Society of Nephrology (ASN)....

Wall Street Analysts See a 192% Upside in Omeros (OMER): Can the Stock Really Move This High?

November 4, 2021zacks.com

The average of price targets set by Wall Street analysts indicates a potential upside of 192% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021

November 4, 2021businesswire.com

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2021, on Tuesday, November 9, 2021, after the market closes. Omeros management will host a conference call...